Isogen 125mg uses are: 

• Treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer.

Isogen 125 mg works by blocking the protein called cyclin-dependent kinases 4 and 6, which are vital for the division and growth of cells. By blocking these proteins, this medication slows the growth and prevents the cancer cells from spreading. 

Inform your doctor about all medications including prescribed, over-the-counter, nutritional or vitamin supplements and herbal products that you are taking or have taken before the treatment. Concurrent use of palbociclib with CYP3A4 inhibitors such as fentanyl has reported increased fentanyl toxicity. certain medications may interact with the effectiveness of this drug. 

• Keep Isogen 125 mg out of sight and reach of children.
• Store at 20°C to 25°C.

Take Isogen 125 mg exactly as prescribed by your doctor. Take this medication once a day at the same time with food. Swallow this capsule as a whole with a glass of water. Avoid crushing, breaking, or chewing the capsule. 

Isogen side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Isogen 125mg capsule side effects are

Serious:

• Blood disorder (fever, chills, shortness of breath, weakness, bleeding, or bruising)

• Lung inflammation (chest pain, dry cough, or difficulty breathing)

Common:

• Tiredness

• Hair loss

• Dry skin, rash

• Infections

• Low blood cell counts

• Decreased of appetite

• Nausea, vomiting

• Diarrhea

• Swelling of lips and mouth

• Changes in taste

• Nose bleed

• Dry eye, blurred vision, increased tearing

• Avoid grapefruit, grapefruit juice, and St. John’s wort while taking Isogen 125 mg.

• Use effective birth control during treatment and after the final isogen dosage (at least 3 weeks for females and 14 weeks for males).

• This medicine may affect fertility and blood cells, so consult your doctor and follow up with regular blood tests.

1. Pfizer Limited, Electronic medicines compendium (emc), [Revised on June 2021] [ Accessed on 26 Nov 2022], https://www.medicines.org.uk/emc/files/pil.4449.pdf

2. Pfizer Labs, US Food and Drug Administration, [Revised on March 2017] [ Accessed on 26 Nov 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf

3. Neha S Mangini et al; Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer; The Annals of Pharmacotherapy; Published on Nov 2015; Accessed on 26/11/2022; https://pubmed.ncbi.nlm.nih.gov/26324355/

4. Palbace; Pfizer; Revised on Oct 2021; Accessed on 26/11/2022; https://labeling.pfizer.com/ShowLabeling.aspx?id=14029